Truqap, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Truqap

Capivasertib

Prescription required

$13790.00

160mg · 64 tablets

BrandBranded medicine· By AstraZeneca

Strength

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

160mg

200mg

About Truqap

Overview

Truqap (capivasertib) is a prescription cancer medicine for adults, supplied as tablets. It is used with fulvestrant for HR-positive, HER2-negative breast cancer that is locally advanced or has spread, has a PIK3CA, AKT1 or PTEN alteration confirmed by an FDA-authorized test, and has progressed after endocrine-based treatment for metastatic disease or returned during or within 12 months of completing adjuvant therapy. It is also used with abiraterone and prednisone for metastatic prostate cancer that is androgen pathway modulation-naïve or -sensitive and is PTEN-deficient, as confirmed by an FDA-authorized test. It works by blocking AKT proteins involved in signals that support cancer cell growth.

What it treats

- Hormone receptor (HR)-positive, HER2-negative breast cancer in adults that is locally advanced or has spread to other parts of the body, with one or more PIK3CA, AKT1 or PTEN alterations confirmed by an FDA-authorized test. Used with fulvestrant after progression on at least one endocrine-based treatment for metastatic disease, or recurrence during or within 12 months of completing adjuvant therapy. - PTEN-deficient prostate cancer in adults that has spread to other parts of the body and is androgen pathway modulation-naïve or -sensitive. PTEN deficiency must be confirmed by an FDA-authorized test. Used with abiraterone and prednisone.

Safety information

Side effects

Common side effects of Truqap include diarrhea, skin reactions and tiredness. Nausea, vomiting and mouth inflammation are also common in patients with breast cancer. Common blood test changes include increased blood sugar, triglycerides and creatinine, and reduced hemoglobin and certain white blood cells. In patients with prostate cancer, common changes also include low potassium, low sodium and increased liver enzymes. Truqap can cause severely high blood sugar, including diabetic ketoacidosis, which can be fatal. Blood sugar and HbA1c need checking before treatment and regularly during treatment. Contact your doctor if you develop high blood sugar or skin reactions. If diarrhea occurs, increase oral fluids, start antidiarrheal treatment and contact your healthcare provider. Depending on severity, these reactions may require your prescriber to interrupt, adjust or permanently stop treatment. Truqap can harm an unborn baby. Use effective contraception and contact your doctor if you become pregnant during treatment.

When to call your doctor

- Contact your healthcare provider right away if you develop diarrhea. - Seek medical attention for new or worsening skin reactions.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Truqap if you have a severe allergy to capivasertib or any of its ingredients. Truqap can cause severely high blood sugar, including diabetic ketoacidosis, which can be fatal. Blood glucose and HbA1c should be checked before treatment and regularly during treatment. Diarrhea occurs in most patients. If it develops, increase fluid intake, start antidiarrheal treatment and contact your healthcare provider. Skin reactions also require monitoring. Depending on the severity of these side effects, your prescriber may interrupt, reduce or permanently stop treatment. Truqap can harm an unborn baby. Use effective contraception, and consult the fulvestrant prescribing information for its pregnancy and contraception guidance. Do not breastfeed during treatment.

Interactions

Tell your doctor about all medicines and supplements you take. TRUQAP should not be used with strong CYP3A inhibitors unless the combination cannot be avoided; in that case, your prescriber will need to reduce your TRUQAP dose. Moderate CYP3A inhibitors also require a dose reduction. Avoid using TRUQAP with strong or moderate CYP3A inducers. Do not change your dose yourself.

Using Truqap

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label TRUQAP (CAPIVASERTIB) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines